US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

CytoDyn Inc.

0.3030

+0.00290.97%

Volume:1.78M

Turnover:537.13K

Market Cap:415.03M

PE:-7.95

High:0.3130

Open:0.3050

Low:0.2900

Close:0.3001

52wk High:0.3970

52wk Low:0.2050

Shares:1.37B

Float Shares:1.37B

Volume Ratio:0.75

T/O Rate:0.13%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.0381

EPS(LYR):-0.2868

ROE:1659.17%

ROA:-67.45%

PB:-3.98

PE(LYR):-1.06

Loading ...

Overview Company News Filings

CytoDyn CFO Hoffman presents at LD Micro Invitational XVI conference

CytoDyn doses first patient in TNBC expanded access program for leronlimab

Cytodyn Announces First Patient Dosed in Expanded Access Program for Leronlimab in Triple-Negative Breast Cancer

THOMSON REUTERS

CytoDyn to host investor webcast with corporate, clinical update

CytoDyn completes enrollment in Phase 2 metastatic colorectal cancer study

CytoDyn presents new leronlimab data in metastatic triple-negative breast cancer at AACR

CytoDyn reports preliminary phase 2 leronlimab combo data in metastatic colorectal cancer

CytoDyn Q3 FY26 net loss narrows 1% to $4.7 million

CytoDyn extends $28.5 million notes to 2029 and cuts interest rate to 5%

CytoDyn to launch pilot glioblastoma study of leronlimab with temozolomide or radiation

BRIEF-Cytodyn Closes $17.5 Million Financing To Fund Continued Development Of Leronlimab

Press Release: CytoDyn Closes $17.5 Million Financing to Fund Continued Development of Leronlimab

CytoDyn Closes $17.5 Million Private Placement Financing

Cytodyn Closes $17.5 Million Financing to Fund Continued Development of Leronlimab

THOMSON REUTERS

CytoDyn Reports New Leronlimab Survival and Mechanism Data in Metastatic Triple-Negative Breast Cancer at AACR IO

CytoDyn announces benefactor committed funding to support EAP

Cytodyn Announces Funding and Initiation of Expanded Access Program for Patients With Triple-Negative Breast Cancer

THOMSON REUTERS

CytoDyn Inc. reports Q2 net loss of USD 22.6 million, widening nearly 5 times

CytoDyn Reports Leronlimab Boosts PD-L1 and Extends Survival in Metastatic Triple-Negative Breast Cancer

CytoDyn Reaches Settlement in Securities Class Action Lawsuit

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/CYDY/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"CYDY","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CYDY\",,,,,undefined,":{"symbol":"CYDY","market":"US","secType":"STK","nameCN":"CytoDyn Inc.","latestPrice":0.303,"timestamp":1780084800000,"preClose":0.3001,"halted":0,"volume":1775651,"delay":15,"changeRate":0.00966344551816066,"floatShares":1369571229,"shares":1369733680,"eps":-0.03809,"marketStatus":"Market Closed","change":0.0029,"latestTime":"05-29 16:00:00 EDT Delay","open":0.305,"high":0.313,"low":0.29,"amount":537125.7499800003,"amplitude":0.076641,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"otc":true,"ttmEps":-0.03809,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1780300800000},"marketStatusCode":7,"adr":0,"adrRate":0,"exchange":"OTCQB","adjPreClose":0.3001,"volumeRatio":0.7530519442081669},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CYDY\",,,,,undefined,":{"symbol":"CYDY","floatShares":1369571229,"roa":"-67.45%","roe":"1659.17%","lyrEps":-0.286757,"volumeRatio":0.7530519442081669,"shares":1369733680,"dividePrice":0,"high":0.313,"amplitude":0.076641,"preClose":0.3001,"low":0.29,"week52Low":0.205,"pbRate":"-3.98","week52High":0.397,"institutionHeld":0,"latestPrice":0.303,"eps":-0.03809,"divideRate":0,"volume":1775651,"delay":15,"ttmEps":-0.03809,"open":0.305,"prevYearClose":0.28,"prevWeekClose":0.339,"prevMonthClose":0.3097,"prevQuarterClose":0.274,"fiveDayClose":0.3485,"twentyDayClose":0.3097,"sixtyDayClose":0.242},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/CYDY\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-01-14","symbol":"CYDY","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1736830800000,"reportTimeType":"post","actualEps":null},{"market":"US","date":"2024-10-15","symbol":"CYDY","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1728964800000,"reportTimeType":"post","actualEps":null},{"market":"US","date":"2024-08-15","symbol":"CYDY","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1723694400000,"reportTimeType":"post","actualEps":null},{"market":"US","date":"2024-04-15","symbol":"CYDY","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1713153600000,"reportTimeType":"post","actualEps":null},{"market":"US","date":"2024-01-16","symbol":"CYDY","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1705381200000,"reportTimeType":"post","actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"CYDY\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"CYDY\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"CYDY\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2635038084","title":"CytoDyn CFO Hoffman presents at LD Micro Invitational XVI conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2635038084","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635038084?lang=en_us&edition=fundamental","pubTime":"2026-05-15 20:31","pubTimestamp":1778848286,"startTime":"0","endTime":"0","summary":"CytoDyn scheduled to present at LD Micro Invitational XVI in Los Angeles on May 18, 2026 at 10 a.m. PDT.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260515:nNDL2sX3Bd:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IE00BKPKM429.USD","SG9999014013.SGD","IE00BN0W2V16.EUR","BK4585","SG9999014021.USD","IE00BN0W2W23.USD","NDAQ","IE00B3QW5Z07.USD","CYDY","LU2095319765.USD","IE00BGHQF748.EUR","LU2210149790.SGD","SG9999014005.SGD","LU2210150020.SGD","IE00BN0W2T93.GBP","LU0314104364.USD","BK4588","SG9999014039.USD","BK4112","IE00B64PRP62.GBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630399763","title":"CytoDyn doses first patient in TNBC expanded access program for leronlimab","url":"https://stock-news.laohu8.com/highlight/detail?id=2630399763","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630399763?lang=en_us&edition=fundamental","pubTime":"2026-04-27 20:31","pubTimestamp":1777293096,"startTime":"0","endTime":"0","summary":"CytoDyn dosed first patient in an expanded access program for investigational cancer drug leronlimab in triple-negative breast cancer.Program targets patients who have exhausted available treatment options and cannot enroll in ongoing or planned studies.CytoDyn expects real-world use to help clarify leronlimab’s activity in aggressive disease and support development strategy in oncology.Company cited research results already presented at AACR 2026 that it said support further evaluation of leronlimab alongside immune checkpoint inhibitors.Expanded access program is open for physician referrals as CytoDyn works to add participating sites.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260427:nNDL332Tqz:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BN0W2T93.GBP","LU2095319765.USD","BK4139","LU2210150020.SGD","IE00BGHQF748.EUR","SG9999014005.SGD","SG9999014013.SGD","IE00BN0W2W23.USD","LU0314104364.USD","IE00BKPKM429.USD","IE00B64PRP62.GBP","SG9999014021.USD","CYDY","LU2210149790.SGD","IE00BN0W2V16.EUR","NDAQ","BK4585","BK4112","BK4588","IE00B3QW5Z07.USD","SG9999014039.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630787399","title":"Cytodyn Announces First Patient Dosed in Expanded Access Program for Leronlimab in Triple-Negative Breast Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2630787399","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630787399?lang=en_us&edition=fundamental","pubTime":"2026-04-27 20:30","pubTimestamp":1777293001,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260427:nTUA3GWRKV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","CYDY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629831143","title":"CytoDyn to host investor webcast with corporate, clinical update","url":"https://stock-news.laohu8.com/highlight/detail?id=2629831143","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629831143?lang=en_us&edition=fundamental","pubTime":"2026-04-23 20:32","pubTimestamp":1776947572,"startTime":"0","endTime":"0","summary":"CytoDyn schedules investor webcast for April 30, 2026, at 1 p.m. PT to provide corporate update.Webcast to cover clinical progress for leronlimab program, including metastatic triple-negative breast cancer, colorectal cancer.CEO Jacob P. Lalezari set to appear with Pashtoon M. Kasi, City of Hope Orange County, plus CFO Robert E. Hoffman.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260423:nNDL7gxHrR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210149790.SGD","NDAQ","BK4585","SG9999014005.SGD","IE00BGHQF748.EUR","CYDY","LU2095319765.USD","BK4139","IE00B3QW5Z07.USD","SG9999014021.USD","LU0314104364.USD","BK4588","LU2210150020.SGD","BK4112","SG9999014013.SGD","IE00BKPKM429.USD","IE00B64PRP62.GBP","IE00BN0W2T93.GBP","IE00BN0W2W23.USD","IE00BN0W2V16.EUR","SG9999014039.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629389050","title":"CytoDyn completes enrollment in Phase 2 metastatic colorectal cancer study","url":"https://stock-news.laohu8.com/highlight/detail?id=2629389050","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629389050?lang=en_us&edition=fundamental","pubTime":"2026-04-22 04:14","pubTimestamp":1776802479,"startTime":"0","endTime":"0","summary":"CytoDyn completed enrollment in Phase 2 CLOVER trial testing leronlimab with TAS-102 plus bevacizumab in CCR5-positive, microsatellite-stable relapsed or refractory metastatic colorectal cancer.Study enrolled just over 60 patients across seven US clinical sites.Preliminary findings from CytoDyn Phase 2 metastatic colorectal cancer program were already presented at AACR Annual Meeting 2026, signaling clinical activity and biomarker changes without reporting efficacy endpoints.Trial will now move through treatment and follow-up to determine whether adding leronlimab improves outcomes in this hard-to-treat setting.CytoDyn expects to release topline data from CLOVER when available.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260421:nNDLH2mxz:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BGHQF748.EUR","LU0314104364.USD","LU2210149790.SGD","BK4139","LU2210150020.SGD","IE00B64PRP62.GBP","LU2095319765.USD","NDAQ","SG9999014005.SGD","SG9999014039.USD","BK4585","BK4112","SG9999014013.SGD","CYDY","SG9999014021.USD","BK4588","IE00BKPKM429.USD","IE00BN0W2W23.USD","IE00B3QW5Z07.USD","IE00BN0W2V16.EUR","IE00BN0W2T93.GBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628728793","title":"CytoDyn presents new leronlimab data in metastatic triple-negative breast cancer at AACR","url":"https://stock-news.laohu8.com/highlight/detail?id=2628728793","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628728793?lang=en_us&edition=fundamental","pubTime":"2026-04-20 20:31","pubTimestamp":1776688283,"startTime":"0","endTime":"0","summary":"CytoDyn announced new clinical and translational findings for leronlimab in metastatic triple-negative breast cancer, already presented at AACR Annual Meeting 2026.Study readout linked leronlimab treatment to changes consistent with improved sensitivity to immune checkpoint therapy in patients with low baseline PD-L1.Retrospective analysis of 28 heavily pretreated patients associated higher dose intensity, PD-L1 induction, and use with immune checkpoint inhibitors with better survival outcomes.CytoDyn highlighted long-term survival signal, with 5 of 28 patients alive beyond 60 months of follow-up.Update supports strategy to position leronlimab as combination partner in oncology, with focus on overcoming immunotherapy resistance.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260420:nNDL7YfRQJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CYDY","BK4588","IE00B64PRP62.GBP","IE00B3QW5Z07.USD","IE00BN0W2T93.GBP","SG9999014013.SGD","IE00BN0W2W23.USD","SG9999014039.USD","SG9999014005.SGD","NDAQ","BK4112","BK4139","IE00BN0W2V16.EUR","LU2210149790.SGD","SG9999014021.USD","IE00BKPKM429.USD","BK4585","IE00BGHQF748.EUR","LU2095319765.USD","LU2210150020.SGD","LU0314104364.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627403446","title":"CytoDyn reports preliminary phase 2 leronlimab combo data in metastatic colorectal cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2627403446","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627403446?lang=en_us&edition=fundamental","pubTime":"2026-04-14 20:35","pubTimestamp":1776170125,"startTime":"0","endTime":"0","summary":"CytoDyn scheduled two poster presentations on leronlimab at AACR Annual Meeting 2026 in San Diego on April 17-22.First poster will be presented April 19, outlining research that links leronlimab to increased PD-L1 expression and long-term survival when used with an immune checkpoint inhibitor in PD-L1-low metastatic triple-negative breast cancer.Second poster will be presented April 21, detailing preliminary Phase 2 results for leronlimab combined with TAS-102 and bevacizumab in previously treated metastatic colorectal cancer.Company positioned the AACR data as supportive of its strategy to expand leronlimab across solid tumors by targeting CCR5 biology in tumor microenvironment.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260414:nNDL6105gy:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014005.SGD","SG9999014013.SGD","CYDY","IE00BN0W2V16.EUR","IE00BKPKM429.USD","BK4585","LU2095319765.USD","BK4112","SG9999014039.USD","IE00B64PRP62.GBP","BK4588","BK4139","LU0314104364.USD","LU2210150020.SGD","NDAQ","SG9999014021.USD","IE00B3QW5Z07.USD","LU2210149790.SGD","IE00BN0W2W23.USD","IE00BN0W2T93.GBP","IE00BGHQF748.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625094940","title":"CytoDyn Q3 FY26 net loss narrows 1% to $4.7 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2625094940","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625094940?lang=en_us&edition=fundamental","pubTime":"2026-04-08 20:33","pubTimestamp":1775651605,"startTime":"0","endTime":"0","summary":"CytoDyn posted a net loss of $4.7 million for fiscal Q3 ended Feb. 28, 2026, little changed from year-ago levels.Cash and cash equivalents rose to about $15.7 million, while short-term liabilities totaled about $50.4 million.Management said it may need significant additional funding to execute its leronlimab development strategy, including pursuing non-dilutive options such as licensing and strategic partnerships.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CytoDyn Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 08, 2026, and is solely responsible for the information contain","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260408:nNDL9ss8XM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CYDY","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622015762","title":"CytoDyn extends $28.5 million notes to 2029 and cuts interest rate to 5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2622015762","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622015762?lang=en_us&edition=fundamental","pubTime":"2026-03-25 05:16","pubTimestamp":1774386975,"startTime":"0","endTime":"0","summary":"CytoDyn agreed with the holders of two secured convertible promissory notes to extend each note’s maturity by 36 months.The extended maturity dates are April 5, 2029 and April 23, 2029.As consideration, the company will make monthly payments totaling USD 1.0 million in common stock, priced at the lower of the prior day’s close or the five-day average close.The annual interest rate on each note was reduced to 5% as part of the extension.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CytoDyn Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 24, 2026, and is solely responsible for ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"ab6e84fb0542480d9cf75cb6a9fe5601","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260324:nNDL3xR3PK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CYDY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621626710","title":"CytoDyn to launch pilot glioblastoma study of leronlimab with temozolomide or radiation","url":"https://stock-news.laohu8.com/highlight/detail?id=2621626710","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621626710?lang=en_us&edition=fundamental","pubTime":"2026-03-24 20:31","pubTimestamp":1774355505,"startTime":"0","endTime":"0","summary":"CytoDyn reported that preclinical and translational data on leronlimab, a CCR5-targeting monoclonal antibody, were presented at the AACR Special Conference in Cancer Research: Brain Cancer.In an analysis of 154 primary glioblastoma tumors, CCR5 expression was higher than in normal brain tissue and was associated with poor prognosis.Cell-line experiments showed CCR5 inhibition with leronlimab or maraviroc had functional synergy with temozolomide, and leronlimab pretreatment increased radiation-induced cytotoxicity.CytoDyn said these findings support plans to initiate a pilot study evaluating leronlimab in glioblastoma.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"ab6e84fb0542480d9cf75cb6a9fe5601","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260324:nNDL1wDSbC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CYDY","IE00BN0W2W23.USD","LU2210149790.SGD","LU2210150020.SGD","LU2095319765.USD","IE00B3QW5Z07.USD","NDAQ","SG9999014039.USD","BK4588","IE00BN0W2V16.EUR","IE00BGHQF748.EUR","IE00B64PRP62.GBP","IE00BN0W2T93.GBP","SG9999014021.USD","SG9999014005.SGD","IE00BKPKM429.USD","LU0314104364.USD","SG9999014013.SGD","BK4112","CLDX","BK4139","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617487540","title":"BRIEF-Cytodyn Closes $17.5 Million Financing To Fund Continued Development Of Leronlimab","url":"https://stock-news.laohu8.com/highlight/detail?id=2617487540","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617487540?lang=en_us&edition=fundamental","pubTime":"2026-03-05 21:31","pubTimestamp":1772717502,"startTime":"0","endTime":"0","summary":"BRIEF-Cytodyn Closes $17.5 Million Financing To Fund Continued Development Of LeronlimabMarch 5 (Reuters) - Cytodyn Inc CYDY.PK:CYTODYN CLOSES $17.5 MILLION FINANCING TO FUND CONTINUED DEVELOPMENT OF ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260305:nTUA3W4QQK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CYDY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617404955","title":"Press Release: CytoDyn Closes $17.5 Million Financing to Fund Continued Development of Leronlimab","url":"https://stock-news.laohu8.com/highlight/detail?id=2617404955","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617404955?lang=en_us&edition=fundamental","pubTime":"2026-03-05 21:31","pubTimestamp":1772717460,"startTime":"0","endTime":"0","summary":"VANCOUVER, Washington, March 05, 2026  -- CytoDyn Inc.  , a clinical-stage oncology company advancing leronlimab, a first-in-class humanized monoclonal antibody targeting the CCR5 receptor with therapeutic potential across multiple indications, including triple-negative breast cancer  and metastatic colorectal cancer , today announced that it has closed on a financing of $17.5 million in gross proceeds, with Paulson Investment Company acting as placement agent.The demand from both new and current investors highlights confidence in CytoDyn's clinical progress and its versatile development strategy in immuno-oncology, exploring a number of potential roles for leronlimab -- the Company's first-in-class humanized monoclonal antibody that targets the CCR5 receptor.\"The successful completion of this financing in a challenging capital markets environment reflects meaningful investor support for our clinical strategy,\" said Robert E. Hoffman, CFO of CytoDyn. \"The financing strengthens our bala","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CYDY","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617540123","title":"CytoDyn Closes $17.5 Million Private Placement Financing","url":"https://stock-news.laohu8.com/highlight/detail?id=2617540123","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617540123?lang=en_us&edition=fundamental","pubTime":"2026-03-05 21:30","pubTimestamp":1772717458,"startTime":"0","endTime":"0","summary":"CytoDyn Inc. said it closed a $17.5 million financing with Paulson Investment Company acting as placement agent. The company said the proceeds are expected to fund operations into 2027 and support continued development of leronlimab, including clinical trials, regulatory engagement and data analysis, with additional funds potentially used for manufacturing readiness and general working capital.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260305:nNDLsjL78:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B64PRP62.GBP","LU2210149790.SGD","NDAQ","IE00B3QW5Z07.USD","BK4112","SG9999014005.SGD","LU0314104364.USD","SG9999014021.USD","SG9999014013.SGD","IE00BGHQF748.EUR","LU2210150020.SGD","BK4585","SG9999014039.USD","CYDY","BK4588","LU2095319765.USD","IE00BKPKM429.USD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617540904","title":"Cytodyn Closes $17.5 Million Financing to Fund Continued Development of Leronlimab","url":"https://stock-news.laohu8.com/highlight/detail?id=2617540904","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617540904?lang=en_us&edition=fundamental","pubTime":"2026-03-05 21:30","pubTimestamp":1772717401,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260305:nTUA3W4QQK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","CYDY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2612759262","title":"CytoDyn Reports New Leronlimab Survival and Mechanism Data in Metastatic Triple-Negative Breast Cancer at AACR IO","url":"https://stock-news.laohu8.com/highlight/detail?id=2612759262","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612759262?lang=en_us&edition=fundamental","pubTime":"2026-02-20 21:30","pubTimestamp":1771594216,"startTime":"0","endTime":"0","summary":"CytoDyn Inc. announced new preclinical, translational, and retrospective clinical findings supporting its CCR5-targeting monoclonal antibody leronlimab in metastatic triple-negative breast cancer , including a pooled analysis of 28 heavily pretreated patients from three trials and mechanistic data on T-cell exhaustion pathways and PD-L1/PD1 biology. The company said the data were presented at the AACR Immuno-Oncology Conference held February 18–21, 2026, including a poster presentation on February 19, 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CytoDyn Inc. published the original content used to generate this news brief via GlobeNewswire  on February 20, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260220:nNDL10hNxH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4112","IE00BKPKM429.USD","LU2095319765.USD","SG9999014013.SGD","SG9999014021.USD","BK4585","BK4139","LU0314104364.USD","NDAQ","IE00B64PRP62.GBP","IE00BGHQF748.EUR","SG9999014039.USD","LU2210149790.SGD","SG9999014005.SGD","BK4588","IE00B3QW5Z07.USD","CYDY","LU2210150020.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2606787363","title":"CytoDyn announces benefactor committed funding to support EAP","url":"https://stock-news.laohu8.com/highlight/detail?id=2606787363","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606787363?lang=en_us&edition=fundamental","pubTime":"2026-01-27 21:40","pubTimestamp":1769521219,"startTime":"0","endTime":"0","summary":"CytoDyn (CYDY) announced that a benefactor has formally committed funding to support the Company’s Expanded Access Program, EAP, for patients with ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/cytodyn-announces-benefactor-committed-funding-to-support-eap-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/cytodyn-announces-benefactor-committed-funding-to-support-eap-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CYDY","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2606782120","title":"Cytodyn Announces Funding and Initiation of Expanded Access Program for Patients With Triple-Negative Breast Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2606782120","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606782120?lang=en_us&edition=fundamental","pubTime":"2026-01-27 21:30","pubTimestamp":1769520602,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260127:nTUABCMRNN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CYDY","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2602379881","title":"CytoDyn Inc. reports Q2 net loss of USD 22.6 million, widening nearly 5 times","url":"https://stock-news.laohu8.com/highlight/detail?id=2602379881","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602379881?lang=en_us&edition=fundamental","pubTime":"2026-01-09 21:31","pubTimestamp":1767965496,"startTime":"0","endTime":"0","summary":"CytoDyn Inc. reported a net loss of USD 22.6 million for the quarter ending November 30, 2025. Total interest and other expenses for the quarter amounted to USD 919 thousand. No income tax benefit was recognized during the period. Loss per share data was not disclosed in the provided information.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CytoDyn Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on January 09, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260109:nNDL4HswCQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CYDY","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2589355624","title":"CytoDyn Reports Leronlimab Boosts PD-L1 and Extends Survival in Metastatic Triple-Negative Breast Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2589355624","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589355624?lang=en_us&edition=fundamental","pubTime":"2025-12-08 21:30","pubTimestamp":1765200658,"startTime":"0","endTime":"0","summary":"CytoDyn Inc., a clinical-stage oncology company, announced updated results from a retrospective follow-up analysis involving 28 women with metastatic triple-negative breast cancer  who participated in three leronlimab clinical trials. The findings, which will be presented as a poster at the San Antonio Breast Cancer Symposium on December 12, 2025, indicate that leronlimab treatment is associated with upregulation of PD-L1 in circulating tumor cells and cancer-associated macrophage-like cells. Among patients who demonstrated significant PD-L1 induction and subsequently received immune checkpoint inhibitors, all remain alive after a median of 60.9 months, with three showing no evidence of disease. No dose-limiting toxicities were observed, and no patients withdrew due to treatment-related adverse events. A copy of the presentation will be made available on CytoDyn's website after the symposium.Disclaimer: This news brief was created by Public Technologies  using generative artificial int","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251208:nNDL7VrqfZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NDAQ","CYDY","BK4112","BK4139","IE00B3QW5Z07.USD","IE00BKPKM429.USD","LU2210149790.SGD","SG9999014013.SGD","SG9999014021.USD","SG9999014039.USD","SG9999014005.SGD","BK4588","BK4585","IE00BGHQF748.EUR","LU2095319765.USD","LU2210150020.SGD","IE00B64PRP62.GBP","LU0314104364.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2588786557","title":"CytoDyn Reaches Settlement in Securities Class Action Lawsuit","url":"https://stock-news.laohu8.com/highlight/detail?id=2588786557","media":"Reuters","labels":["policyRegulatory","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588786557?lang=en_us&edition=fundamental","pubTime":"2025-12-01 21:30","pubTimestamp":1764595811,"startTime":"0","endTime":"0","summary":"CytoDyn Inc. has reached an agreement in principle to resolve a securities class action lawsuit that was initially filed in March 2021 against the company and certain former officers. The case, pending in the United States District Court for the Western District of Washington and titled Courter et al. v. CytoDyn Inc. et al., is subject to final court approval. The settlement is expected to provide clarity and finality for the company and its stakeholders. CytoDyn stated that resolving the litigation allows the company to focus on advancing its clinical development programs, including new Phase II studies for leronlimab in metastatic colorectal cancer and metastatic triple-negative breast cancer. Additional information has been included in the company's filings with the Securities and Exchange Commission.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generate","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251201:nNDL65ywfw:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BKPKM429.USD","NDAQ","LU2210149790.SGD","LU2095319765.USD","IE00B3QW5Z07.USD","IE00B64PRP62.GBP","LU0314104364.USD","BK4588","BK4112","CYDY","IE00BGHQF748.EUR","LU2210150020.SGD","BK4139","BK4585"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":21,"code":"91000000","status":"200"}]}}